A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study

被引：1

作者：

Giovannoni, Gavin ^{[1
]}

Boyko, Alexey ^{[2
]}

Correale, Jorge ^{[3
]}

Edan, Gilles ^{[4
]}

Freedman, Mark S. ^{[5
,6
]}

Montalban, Xavier ^{[7
]}

Rammohan, Kottil ^{[8
]}

Stefoski, Dusan ^{[9
]}

Yamout, Bassem ^{[10
,11
]}

Leist, Thomas

Aydemir, Aida ^{[12
]}

Borsi, Laszlo

di Cantogno, Elisabetta Verdun ^{[12
]}

机构：

[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England

[2] Pirogov Russian Natl Res Med Univ, Fed Ctr Brain Res & Neurotechnol, Dept Neurol Neurosurg & Med Genet, Moscow, Russia

[3] FLENI Inst, Dept Neurol, Buenos Aires, Argentina

[4] Univ Hosp Rennes, Dept Neurol, Rennes, France

[5] Univ Ottawa, Dept Med, Ottawa, ON, Canada

[6] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[7] Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain

[8] Univ Miami, MS Res Ctr, Sch Med, Miami, FL USA

[9] Rush Med Coll, Dept Neurol Sci, Chicago, IL USA

[10] Harley St Med Ctr, Neurol Inst, Abu Dhabi, U Arab Emirates

[11] Amer Univ, Beirut Med Ctr, Beirut, Lebanon

[12] Merck KGaA, Darmstadt, Germany

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2023年 / 13卷 / 05期

关键词：

D O I：

10.2217/nmt-2023-0018

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

What is this summary about? Previous studies have shown that people living with multiple sclerosis ( MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. What were the results? Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. What do the results mean? The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.

引用

页码：261 / 268

页数：8

共 50 条

[31] Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Meuth, Sven G.
Bayas, Antonios
Kallmann, Boris
Linker, Ralf
Rieckmann, Peter
Wattjes, Mike P.
Maeurer, Mathias
Kleinschnitz, Christoph
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1503 - 1510
[32] People with multiple sclerosis in their 5th year of treatment with cladribine: Long-term observation of the German MS Register
Ellenberger, David
Frahm, Niklas
Firas, Fneish
Peters, Melanie
Flachenecker, Peter
Friede, Tim
Paul, Friedemann
Warnke, Clemens
Zettl, Uwe K.
Stahmann, Alexander
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 642 - 643
[33] Classic-ms: long-term efficacy and real-world treatment patterns for patients receiving cladribine tablets - interim data with 8-14 years follow-up
Giovannoni, G.
Leist, T.
Aydemir, A.
Di Cantogno, E. Verdun
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 90 - 90
[34] Long-term effectiveness of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene: a plain language summary
Judge, Daniel P.
Lakdawala, Neal K.
Taylor, Matthew R. G.
Mestroni, Luisa
Li, Huihua
Oliver, Colleen
Angeli, Franca S.
Lee, Patrice A.
MacRae, Calum A.
FUTURE CARDIOLOGY, 2023, 19 (03) : 117 - 126
[35] Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study
Selmaj, Krzysztof
Langdon, Dawn
Brochet, Bruno
Solari, Alessandra
Havrdova, Eva Kubala
Patti, Francesco
Piehl, Fredrik
Smyk, Andrzej
Lehn, Annette
Nolting, Axel
Montalban, Xavier
Lechner-Scott, Jeannette
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 655 - 657
[36] Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy
Filippi, Massimo
Ferre, Laura
Zanetta, Chiara
Rizzi, Caterina
Pessina, Gabriella
Assogna, Francesco
Rocca, Maria A.
FRONTIERS IN NEUROLOGY, 2024, 15
[37] Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data
Bell, CF
Graham, JB
Earnshaw, SR
Oleen-Burkey, M
Castelli-Haley, J
Johnson, KP
VALUE IN HEALTH, 2006, 9 (03) : A81 - A82
[38] Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
Druart, Charlotte
El Sankari, Souraya
van Pesch, Vincent
PATIENT-RELATED OUTCOME MEASURES, 2018, 9 : 1 - 10
[39] Plain language summary on long-term effectiveness of eculizumab: Data from the International PNH Registry
不详
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (04) : 658 - 658
[40] CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study
Fink, K.
Nilsson, P.
Alonso, L.
Sveningsson, A.
Gunnarsson, M.
Lange, N.
Ayad, A.
Vrethem, M.
Burman, J.
Lycke, J.
Piehl, F.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 847 - 848

← 1 2 3 4 5 →